Seroprevalence of SARS-CoV-2 antibodies in South Korea
From MaRDI portal
Publication:2132033
Abstract: In , Korea Disease Control and Prevention Agency reported three rounds of surveys on seroprevalence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies in South Korea. We analyze the seroprevalence surveys using a Bayesian method with an informative prior distribution on the seroprevalence parameter, and the sensitivity and specificity of the diagnostic test. We construct the informative prior using the posterior distribution obtained from the clinical evaluation data based on the plaque reduction neutralization test. The constraint of the seroprevalence parameter induced from the known confirmed coronavirus 2019 cases can be imposed naturally in the proposed Bayesian model. We also prove that the confidence interval of the seroprevalence parameter based on the Rao's test can be the empty set, while the Bayesian method renders a reasonable interval estimator. As of the th of October , the credible interval of the estimated SARS-CoV-2 positive population does not exceed , approximately of the Korean population.
Recommendations
- Estimation of Covid-19 prevalence from serology tests: a partial identification approach
- Estimating the cumulative rate of SARS-CoV-2 infection
- Analysis of serological surveys of antibodies to SARS-CoV-2 in the United States to estimate parameters needed for transmission modeling and to evaluate and improve the accuracy of predictions
- Prevalence estimation and optimal classification methods to account for time dependence in antibody levels
- Visualizing the invisible: the effect of asymptomatic transmission on the outbreak dynamics of COVID-19
Cites work
Cited in
(2)
This page was built for publication: Seroprevalence of SARS-CoV-2 antibodies in South Korea
Report a bug (only for logged in users!)Click here to report a bug for this page (MaRDI item Q2132033)